E34.321
Primary insulin-like growth factor-1 (IGF-1) deficiency
Clinical Classification Guidelines
Inclusion Terms
- Acid-labile subunit gene (IGFALS) defect
- Growth hormone gene 1 (GH1) defect with growth hormone neutralizing antibodies
- Growth hormone insensitivity syndrome (GHIS)
- Insulin-like growth factor 1 gene (IGF1) defect
- Laron type short stature
- Severe primary insulin-like growth factor-1 deficiency (SPIGFD)
- Signal transducer and activator of transcription 5B gene (STAT5b) defect
Medical Intelligence & Overview
Primary insulin-like growth factor-1 (IGF-1) deficiency is a rare condition characterized by low levels of IGF-1, a hormone vital for childhood growth and metabolic functions. This disorder is often linked to genetic mutations affecting how the body produces or responds to IGF-1. It can manifest as growth failure in children and may be associated with various genetic syndromes such as Laron syndrome or severe primary IGF-1 deficiency. Recognizing this condition early is important for managing growth delays and associated health issues.
Causes & Symptoms
Clinical Causes: Genetic mutations affecting the IGF-1 gene (IGF1) Defects in the acid-labile subunit gene (IGFALS) Mutations in the growth hormone gene (GH1) leading to growth hormone insensitivity Mutations affecting signal transducer and activator of transcription 5B (STAT5b) Development of growth hormone neutralizing antibodies Other genetic syndromes like Laron syndrome and GH insensitivity syndromes
Key Symptoms: Significant growth delay or short stature occurring in childhood Normal or elevated levels of growth hormone with low IGF-1 levels Delayed or absent secondary sexual characteristics in adolescents Possible features associated with syndromic forms, such as distinctive facial features Low energy and fatigue which may be related to metabolic disturbances Potential developmental delays depending on severity and underlying mutation
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a combination of clinical assessment and laboratory testing. It typically includes measuring serum levels of IGF-1, growth hormone, and other related factors. Genetic testing can identify mutations in the IGF1 gene, IGFALS gene, GH1, or STAT5b. Imaging studies, such as skeletal surveys, may be performed to evaluate growth delays. The diagnosis aims to differentiate primary IGF-1 deficiency from other growth disorders and to understand the underlying genetic causes.
Treatment Protocols: Management strategies focus on addressing growth failure and related metabolic issues. Treatment options may include IGF-1 therapy to stimulate growth in children with confirmed deficiencies. Regular monitoring by healthcare providers ensures appropriate dosing and assessment of response. Supportive care can involve nutritional counseling and addressing any associated health issues. In certain cases, hormone therapy may be combined with other interventions depending on individual needs and response.
Clinical Advice & FAQs
Billing Guidance
Is E34.321 a billable ICD-10 code?
Yes, E34.321 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E34.321?
Clinical documentation must specify the nature of Primary insulin-like growth factor-1 (IGF-1) deficiency and any associated comorbidities for accurate reporting.
Cite this Clinical Reference